Publication details

Léčba agonisty receptoru pro GLP1 a kontrola hmotnosti

Title in English Treatment of GLP1 receptor agonists and body mass control
Authors

ŽÁK Petr OLŠOVSKÝ Jindřich

Year of publication 2015
Type Article in Periodical
Magazine / Source Vnitřní lékařství
MU Faculty or unit

Faculty of Medicine

Citation
Field Other specializations of internal medicine
Keywords agonists of the GLP1 receptor; diabetes mellitus; obesity
Description The prevalence of obesity continues to be increasing in all age groups in most countries of the European Union (ED). Many obese people have a history of several successful weight losses, but very few are able to maintain the weight loss over a longer period of time. Initiation of the GLP1 RA administration during weight loss maintenance would inhibit weight loss-induced increases in soluble leptin receptor plasma concentrations resulting in higher level of free leptin thereby preventing weight regain. In contrast initiation of insulin treatment in type 2 diabetes patients is frequently accompanied with weight gain. The GLP1 administration results in HbAlc decrease accompanied with weight loss, presents attractive alternative to basal insulin. The question remains to be answered in the future, if the GLP1 RA administration is generally more frequently started in antiobese than antidiabetes implication.

You are running an old browser version. We recommend updating your browser to its latest version.

More info